NOVARTIS

Abata Therapeutics' ABA-101, an autologous Treg therapy for progressive MS, received FDA fast track designation. It shows a tolerable safety profile and potential therapeutic effect, aiming to treat progressive MS patients with ongoing inflammatory tissue injury and who are HLA-DRB1*15:01 positive.

JFK, PL, CCW, TYW, XZ, PMW, SL, LB, ZH, SF, KWC, KR, and SS have various consulting roles, advisory board memberships, or research support from numerous pharmaceutical and medical technology companies.

At the ESC conference, Thomas Hauser presented results showing Novartis's XXB750, a natriuretic peptide receptor A agonist, is safe and well tolerated in chronic stable HF patients with reduced or mildly reduced EF, administered subcutaneously. The study supports monthly dosing, with mild adverse events observed.

Twice-yearly inclisiran (Leqvio; Novartis) monotherapy demonstrated clinically meaningful and statistically significant LDL-C lowering in patients at low or moderate risk of ASCVD, surpassing both placebo and ezetimibe, according to a Novartis press release.

Novartis' Phase III study of Leqvio (inclisiran) in low/moderate risk ASCVD patients not on lipid-lowering therapy met primary endpoints, showing significant LDL-C lowering versus placebo and ezetimibe. The VictORION program has enrolled over 60,000 patients in 50+ countries, with inclisiran demonstrating consistent LDL-C reduction beyond six years in addition to statin therapy.

Novartis' Phase III V-MONO trial of Leqvio met primary endpoints, showing significant LDL-C reduction in low/moderate ASCVD risk patients. The trial compared Leqvio monotherapy against ezetimibe and placebo, with findings to be discussed with regulatory authorities.

Leqvio (inclisiran) monotherapy demonstrated superiority in LDL-C reduction vs placebo and ezetimibe in the Phase III V-MONO study, part of the 60,000-patient VictORION program for ASCVD prevention.

The global multiple sclerosis (MS) diagnosis and treatment market, valued at USD 22.14 billion in 2023, is projected to reach USD 28.48 billion by 2031. North America led with a 38.3% market share in 2023, driven by advanced healthcare and R&D. Asia Pacific is expected to grow rapidly, with a 7% CAGR. Relapse-Remitting MS dominated the market, accounting for over 70% share. Medications held 81% of the treatment segment. Innovations and high R&D investments are fueling market growth, despite challenges like high drug costs.

The global biotechnology market, valued at USD 1.55 trillion in 2024, is projected to reach USD 4.61 trillion by 2034, growing at a CAGR of 11.5%. North America led with a 37.79% revenue share in 2023, driven by strong R&D and healthcare spending. Asia-Pacific is expected to grow at over 12.4%, supported by healthcare improvements and government regulations. Key growth factors include technological advancements, rising disease prevalence, and increased R&D investments. Bio-pharmacy dominates the market, with bio-informatics expected to grow rapidly. Tissue engineering and regeneration lead in technology, with chromatography growing fastest.

NST-628 is an oral, brain-penetrant pan-RAF–MEK non-degrading molecular glue that prevents paradoxical pathway activation, differentiating it from other RAS/RAF/MAPK pathway inhibitors.